QualityStocks would like to highlight Advaxis (OTCBB: ADXS), a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to the cancer itself.
In the company’s news yesterday,
Advaxis was chosen to present, in oral and poster form, two abstracts detailing research with Advaxis Lm-LLO immunotherapies. The presentation was held at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting, October 26-28, 2012, at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, MD. This announcement was first made back in August, when the company first received word of being selected.
“With the clinical data to be presented at SITC, Advaxis continues to demonstrate the utility of our novel technology for the treatment of cancer,” said Dr. John Rothman, EVP of Science and Operations at Advaxis. “The commitment of Advaxis to develop new and potentially more versatile strains of Listeria to treat disease is exemplified by the work we will present on a bivalent Lm-LLO vector.”
On September 10th, Thomas Moore, Chairman and CEO of Advaxis, presented at the Rodman & Renshaw 14th Annual Healthcare Conference in the Palm Room of the Waldorf-Astoria Hotel in New York. Slides from the presentation were made available on the Advaxis website.
Additionally, Advaxis recently announced exciting news that the first two dogs have been dosed in the University of Pennsylvania School of Veterinary Medicine study of ADXS-HER2 for canine osteosarcoma. Overseen by Dr. Nichola Mason, Chairman Companion Animal Medicine at the University of Pennsylvania School of Veterinary Medicine, ADXS-HER2 is being used to treat dogs suffering from bone cancer. Canine osteosarcoma, which causes tumors to form on long leg bones, is a leading killer of large breed dogs. Previously, the only treatment for this disease was immediate amputation of the limb, combined with follow-up chemotherapy. The recurring issue is that, typically, the cancer metastasizes and spreads to the lungs, causing death in 6-12 months.
However, using Advaxis agent ADXS-HER2, the trial hopes to improve the lifespan of dogs exhibiting osteosarcoma. This immunotherapy is designed to stimulate the dog’s immune system to attack cancer cells that express the HER-2/neu marker. The primary goal being to elicit anti-tumor immunity and prolong survival.
“We don’t have to wait years to see if we are having an effect,” stated Dr. Nicola Mason. “If we find that these canine patients survive over 12 months, then that is a strong indication that this immunotherapy is in fact providing a therapeutic benefit.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
